Global Allergic Conjunctivitis Market Report by Disease Type (Seasonal ALLERGIC Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC)), Drug class (Antihistamines & Mast Cell Stabilizers, Corticosteroids, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores, Others), Countries and Company Analysis, 2024-2032

Allergic Conjunctivitis Market Analysis

Global Allergic Conjunctivitis Market Outlook

Ocular allergy (OA) is another term that is used interchangeably with allergic conjunctivitis. It is a widespread immunological hypersensitivity illness that affects many different demographic groups. The incidence of allergic conjunctivitis has been rising recently. Its symptoms, which include worldwide irritation, redness, and swelling, greatly reduce a person's quality of life. Furthermore, very few people with allergic conjunctivitis symptoms seek medical assistance; instead, the majority of patients manage their condition with over-the-counter drugs and supplementary non-pharmacological remedies. As a result, allergic conjunctivitis is frequently underdiagnosed and undertreated.

In most cases, conjunctivitis can be self-diagnosed, and testing is not necessary to confirm the condition. Therefore, during the projected period, the incidence of allergic conjunctivitis is anticipated to contribute to the market's growth. Another NIH article from February 2021 states that the two most common types of infectious conjunctivitis are viral and bacterial conjunctivitis. Up to 80% of cases of acute conjunctivitis are caused by viral infections, while between 50 and 75 percent of cases of infectious conjunctivitis in children are caused by bacterial infections.

The same source claims that conjunctivitis is very common in nations like China. Furthermore, mainland China had an average yearly incidence of hemorrhagic conjunctivitis of 3.58/100,000, according to a BMC article published in March 2022. The need for conjunctivitis therapy is anticipated to increase due to the growing prevalence of hemorrhagic conjunctivitis, which will support market expansion.

Driving forces for Allergic Conjunctivitis Market

Expanding Patient Base to Drive Need for Efficient Treatments - The sizeable patient population with ocular allergies is one of the most important and significant key drivers contributing to the growth of the worldwide market. Over 15% of people worldwide are thought to be affected by allergies, which is a serious medical condition. Due to the fact that allergies often impact many body organs, a patient may have symptoms that are specific to several organ systems. However, because it causes persistent, incapacitating symptoms like eye watering and itching that result in severe irritation, the ocular component of an allergy is thought to be the most noticeable and incapacitating aspect of the condition. Due to the significant increase in the patient population over the past few years, there has been a huge surge in the need for treatments such as mast cell stabilizers and antihistamines. The prevalence of this illness has significantly increased during the past 40 years, according to numerous research investigations.

For example, the American Academy of Allergy, Asthma & Immunology estimates that in 2022, approximately 100 million Americans had one or more allergy disorders. Major pharmaceutical companies are placing a greater emphasis on the research and development (R&D) of effective therapies as a result of the disease's rising prevalence, as seen by the products' upcoming strong pipeline. Aldeyra Therapeutics, Inc., for example, released the phase 3 results of the INVIGORATE-2 clinical trial in June 2023, pertaining to the use of 0.25% reproxalap ophthalmic solution for allergic conjunctivitis. These advancements will accelerate the expansion of the allergic conjunctivitis market in the near future.

New Developments in Ocular Allergy Therapeutics R&D to Support Market Expansion - Over the past few decades, there has been a significant increase in the general prevalence of ocular allergies due to a number of variables, including the number of allergens rising and growing industrialization and urbanization.

This has caused several biopharmaceutical companies to become involved in research and development projects aimed at creating potent medications to treat this kind of conjunctivitis. For example, the FDA authorized cetirizine, the first antihistamine available only through prescription, in July 2020 to treat allergic conjunctivitis. It is projected that throughout the forecast period, the market would rise strongly as a result of these R&D initiatives.

There are physiological restrictions on medication bioavailability due to the structure of the eye, which has sparked intense interest in the creation of novel drug delivery methods. A contact lens that delivers the over-the-counter antihistamine/mast cell inhibitor ketotifen for ocular allergies is one of the other R&D activities for therapeutic possibilities. Researchers from all around the world are concentrating on figuring out the disease's underlying mechanism in order to develop a successful treatment for this medical ailment.

For example, according to findings released by the ophthalmic magazine Minivision in October 2023, Japanese researchers have found that specialized epithelial cells are crucial to the development of conjunctival illness. The goal of this research was to identify a new therapeutic target for the management of allergic conjunctivitis.

It is anticipated that these extensive R&D projects will present significant prospects for market expansion down the road.

North America allergic conjunctivitis market

Due to factors like the region's high consumer awareness of conjunctivitis and the simple availability of efficient treatment treatments, North America is anticipated to lead the market. More than 6 million Americans suffer from conjunctivitis annually, according to a February 2020 National Library of Medicine publication. The illness is expected to cost between USD 377 million and USD 857 million annually. According to research, conjunctivitis is the most common illness in the nation, affecting 15% to 40% of people and being most common in the spring and summer.

Additionally, according to an NCBI article from January 2021, seasonal or perennial allergic conjunctivitis accounts for over 95% of ocular allergy cases in the US, making it the most common type of the condition. Between 15% and 40% of people are affected, and it is seen in both sexes. Due to the high frequency of conjunctivitis in the US, there will likely be a demand for efficient treatments, which will fuel market expansion over the course of the projection period.

The US market is anticipated to hold the highest share in the near future due to improved healthcare services and the increasing incidence of conjunctivitis. Moreover, throughout the course of the projected period, Canada's high frequency of conjunctivitis is anticipated to fuel market expansion. According to a BMC article from October 2022, the percentage of Canadians with dry eyes is predicted to be 21%. It is anticipated that this high incidence of conjunctivitis will support market expansion in Canada.

Allergic Conjunctivitis Company Analysis

Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, Novartis AG, Ocular Therapeutix, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are some of the leading competitors of the Allergic conjunctivitis Market.

Global Allergic Conjunctivitis Market News

In July 2023, Santen Pharmaceutical Co., Ltd. and Harrow entered into a deal for Harrow to purchase certain U.S. and Canadian marketing rights for six Santen-branded ophthalmic medications. The acquisition aided in the portfolio expansion of Horrow's ophthalmic products.

In March 2022, The FDA in the United States has approved Johnson & Johnson Vision Care, Inc.'s ACUVUE Theravision with Ketotifen, a drug-eluting contact lens that contains etafilcon and ketotifen.

Disease Types – Global Allergic Conjunctivitis Market is divided into 2 viewpoints

1. Seasonal ALLERGIC Conjunctivitis (SAC)
2. Perennial Allergic Conjunctivitis (PAC)

Drugs Class – Global Allergic Conjunctivitis Market is divided into 3 viewpoints

1. Antihistamines & Mast Cell Stabilizers
2. Corticosteroids
3. Others

Distribution Channels – Global Allergic Conjunctivitis Market is divided into 4 viewpoints

1. Hospital Pharmacies
2. Online Pharmacies
3. Retail Pharmacies & Drug Stores
4. Others

Countries – Market is divided into 25 country Allergic Conjunctivitis Industry

North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. United Arab Emirates

Company Insights:

• Overview
• Operating business segments
• Product portfolio & Product Launch in Last 1 Year
• Recent Developments
• Revenue

Companies Covered:

1. Ajanta Pharma Limited
2. Akorn Operating Company LLC
3. Alembic Pharmaceutical Ltd.
4. Cipla Inc.
5. Indoco Remedies Ltd.
6. Johnson & Johnson
7. Novartis AG
8. Ocular Therapeutix, Inc.
9. Sun Pharmaceutical Industries Ltd.
10. Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

Question:    How big is the Allergic Conjunctivitis market?

Answer:     The global Allergic Conjunctivitis market size was estimated to reach USD 2.40 billion in 2032 while it was estimated to reach US$ 1.96 billion by 2023.

Question:    What is the Allergic Conjunctivitis market growth rate?

Answer:     The global Allergic Conjunctivitis market is expected to grow at a compound annual growth rate of 2.27% from 2024 to 2032.

Question:    Who are the key players in Allergic Conjunctivitis market?

Answer:     Some key players operating in the Allergic Conjunctivitis market include Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, etc.

Question:    What are the factors driving the Allergic Conjunctivitis market?

Answer:     Key factors that are driving the Allergic Conjunctivitis market growth include Expanding Patient Base to Drive Need for Efficient Treatments, New Developments in Ocular Allergy Therapeutics R&D to Support Market Expansion.

Question:    Which Region held the largest market share in the Allergic Conjunctivitis market?

Answer:     “North America” had the largest share in the Allergic Conjunctivitis Market.

Report Details: